Search Results

As Chief Matchmaker, I recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology Mark:  “Beth, why did you decide to join Crinetics?” Beth:  “Yes.  There are a lot of learning opportunities at Crinetics.  Mark:  “Beth, why would someone want you as their boss?” Beth:  “Well, I enjoy training and mentoring team members. 

Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology

Our Chief Matchmaker, Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director

Our Chief Matchmaker, Mark Schmeizl, had a great conversation about this position with Beth Fleck, Director

Stay tuned for further details, as we plan to open registrations for both courses in July 2024. Dr. Mark discussed this position with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

regarding the role of C3aR in controlling bacterial infections and analyze these results in the context of both

September 2022 Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target "Purpose: Beta 2-Adrenergic

Studying the pancreatic islet — specifically the beta cells  that release insulin — offered a unique It affected hormone signaling between alpha and beta cells, but the mechanism was unclear.

October 2022 Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein PKC and mutation of rat mGlu5a Ser901, a PKC-dependent phosphorylation site in the receptor C-tail, both This indicates that isozymes from both classes are involved, compensate for the absence of the other

Eric Trinquet, that moment arrived when his team successfully tracked GPCR internalization in native beta They learned how to fine-tune both brightness and fluorescence lifetime. transformed everything: a clean, dose-dependent response of GLP-1 receptor internalization in native beta synthesis begins Collaborative screening of scaffold families Key milestone: Clean signal in endogenous beta

A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent transcription in One candidate effector of PKA-dependent transcriptional regulation is the BET protein Brd4. However, it is unknown whether BET proteins, or Brd4 specifically, are involved in transcriptional activation Here, we demonstrate that in adult rats, inhibition of BET proteins with the bromodomain inhibitor JQ1 Our findings identify the BET protein family, and Brd4 in particular, as novel regulators of basal and

The model needs to account for the possibility that both arms of the pharmacological response — activation Beta-Arrestin as Gatekeeper: Core Versus Tail Beta-arrestin mediates the transition from surface to cytosol BRET-based assays can quantify beta-arrestin recruitment and, depending on the assay design, distinguish Knockdown studies confirm the dependency: in cells where beta-arrestin expression is reduced, receptor Diffusion-enhanced resonance energy transfer extends this further by capturing both internalization and

Both assays provide unique profiles and a preferred receptor signaling bias for the therapeutics tested Efficacy (comprising of both quality and quantity attributes for different agonists) reveals how an expected Morphine side effects in beta-arrestin 2 knockout mice.

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies." Read more at the source #DrGPCR #GPCR #IndustryNews

Pro-inflammatory GPR4-mediated leukocyte infiltration and C5a receptor-driven platelet hyperactivity have both The methodological advances required to exploit both via multi-pathway functional assays , phenotypic

They both mark critical moments in humanity’s centuries-long quest to control physiology—and they bookend Fast-forward a few thousand years, and we’re talking beta receptors, receptor theory, and AI-generated

trip to London, confocal imaging marathons, and a partnership built on trust and curiosity — reshaped both Signaling waves pulsing across clusters of beta cells. fluorescent probes, how he evaluated biological constraints, and how he approached GPCR imaging as both Over the years, they learned from each other in ways that shifted both careers. experiments that capture receptor dynamics in intact tissue and live animals, expanding what’s possible in both

Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing both 2023: pHSense probes optimized for dual pH response ✅ 2024: Endogenous GLP-1 internalization shown in beta moment with pHSense came the day his team showed internalization of endogenous GLP-1 receptors in rat beta

to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , a conference organized by both the EFMC and the ACSMEDI, in an effort to share the most novel medicinal chemistry advancements in both This joint effort by both associations is repeated every year, with 2026’s being in Dublin, Ireland. The talks given targeted both traditional GPCRs such as the serotoninergic receptor 5HT1A, but also newer

The Steady-State Cancellation Problem A scaffold carrying both agonist and antagonist activity presents In a preparation containing both the full agonist and the antagonist fragment, steady-state observation When a scaffold carries both activities, kinetic assays produce complex time-dependent response curves In real-time observation, both activities emerge as distinct, time-separated signatures: one potentiating

Studying their dynamics in both a spatial and temporal manner is key to understanding how they work in fluorescent probes must have high specificity, minimal phototoxicity and preferably be compatible with both This is why fluorescent tags, both attached to the protein or to pharmacophores, are so interesting. image stacks, facilitating the reconstruction of GPCR distribution in tissue-like environment , in both

in β-arrestin recruitment across class B1 GPCRs  – GPCR mutations in cancer—drivers, passengers, or both Research presents CELT-419, a nanomolar-affinity fluorescent ligand optimized for D3 receptor assays in both GPCR mutations in cancer   show both driver-like patterns and high redundancy, prompting a call for multiomics

Matters Connect with peers across biotech, CROs, and investment who are driving discovery forward Meet both identification, target validation, assay development, compound management, and high-throughput screening in both Screening campaigns can be performed using Axxam’s high-quality compound collections—both synthetic and

Eric Trinquet and his team at Revvity, that moment came when they watched GPCRs internalize in native beta By carefully tuning both brightness and fluorescence lifetime, they engineered a two-dimensional pH response receptor localization and real-time signaling shape therapeutic outcomes, fluorescent ligands deliver both

especially those emerging from cytotoxicity or off-target activities, risks catastrophic consequences for both A scaffold exhibiting hERG inhibition is an immediate candidate for discontinuation, as the risk is both Kenakin clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven

Serafini noted that RGS4 was especially intriguing because it was expressed robustly both in the peripheral system and in central circuits like the prefrontal cortex and thalamus  — areas deeply involved in both

For competition-based screening, antagonists are preferred as they exhibit the same affinity for both A Flow Cytometry C5aR binding assay was performed in both C5aR-HEK (Multispan) and C5aR-Chem1 (DiscoverX Both CELT-58 and SG65 exhibited strong binding properties across different cell lines. Figure 6. Both ligands exhibit high specific binding to C5aR in saturation binding assays (Figure 5) and demonstrate Both are orthosteric ligands with antagonistic activity in Calcium and cAMP assays (Table 1).

C GPCRs, are obligate dimers, either as homodimers or heterodimers, with distinct conformations in both Recent studies suggest that class B1 GPCRs can form both homodimers and heterodimers, which may play that GLP-1R homodimerization occurs via transmembrane helix 4 (TM4), which forms the interface for both result, dimerized SecR receptors exhibit higher rates of G protein activation and release, improving both

receptors belong to class A of G protein-coupled receptors or GPCRs and signaled mainly through Gai/o, beta At the synapse, they are localized in both pre- and postsynaptic compartments and their activation is The authors found that both β-arrestin 1 and 2 are involved in MOR internalization and downstream signaling

why teamwork is non-negotiable) The difference between Me Too  and First in Class  projects—and why both